Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Science

• Publication date

  2001-08-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1126/SCIENCE.1060937PMID 11498597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

  2001cited by this paper
• Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.

  2001cited by this paper
• Objective changes in motor function during placebo treatment in PD

  2000cited by this paper
• Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review

  2000cited by this paper
• The placebo response in Parkinson's disease. Parkinson Study Group.

  1999cited by this paper
• Pills or Placebos?

  1999cited by this paper
• Neuroscience news

  1999cited by this paper
• The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking.

  1999cited by this paper
• How expectancies shape experience.

  1999cited by this paper
• Pills or placebos?

  1999cited by this paper
• Powerful placebo: the dark side of the randomised controlled trial.

  1998cited by this paper
• Predictive reward signal of dopamine neurons.

  1998cited by this paper
• Evidence for striatal dopamine release during a video game

  1998cited by this paper
• Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

  1996cited by this paper
• Concept of true and perceived placebo effects

  1995cited by this paper
• Placebo effect in double-blind clinical trials: a review of interactions with medications.

  1994cited by this paper
• Imaging endogenous dopamine competition with [11C]raclopride in the human brain

  1994cited by this paper
• Biostatistics: A Methodology for the Health Sciences

  1993cited by this paper
• Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain.

  1993cited by this paper
• Functions of dopamine in the dorsal and ventral striatum

  1992cited by this paper
• Ageing and Parkinson's disease: substantia nigra regional selectivity.

  1991cited by this paper
• Practical statistics for medical research

  1990cited by this paper
• Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: Implications for positron emission tomography of the human brain

  1989cited by this paper
• Peripheral pharmacokinetics of apomorphine in humans

  1989cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• The dopamine synapse and the notion of ‘pleasure centers’ in the brain

  1980cited by this paper
• The powerful placebo.

  1955cited by this paper
• Brain

  1878cited by this paper

• Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review

  2026cites this paper
• Beyond Statistical Myopia: Replying to a Misguided Critique of Mind–Body Research

  2026cites this paper
• Dissociating dopaminergic and nondopaminergic motor loads in Parkinson’s disease: clinical correlates, non-motor interactions, and quality-of-life implications

  2026cites this paper
• Reconsidering Placebo Effects in Neuromodulation for Parkinson’s Disease: Lessons for Clinical Trials and Therapeutic Translation

  2026cites this paper
• Placebo Effects in Modern Medicine: Mechanisms, Clinical Evidence, Limitations, and Future Directions

  2026cites this paper
• The role of mindsets in placebo effects and healthcare.

  2025cites this paper
• Phase 1/2a clinical trial of hESC-derived dopamine progenitors in Parkinson's disease.

  2025cites this paper
• A salutogenic signature of the placebo effect in brain oscillations: A systematic review and meta-analysis.

  2025cites this paper
• Placebo effects and emotion regulation: conceptual and neural similarities and differences.

  2025cites this paper
• Public and professional attitudes towards deceptive and open-label placebo in functional neurological disorder and wider neurological practice

  2025cites this paper
• Advancing Neuromodulation for Functional Movement Disorders: A Contemporary Narrative Review of Evidence, Gaps, and Future Outlook.

  2025cites this paper
• Placebo Responses in Trials of Parkinson's Disease.

  2025cites this paper
• Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham-Controlled Clinical Trial

  2025cites this paper
• Placebo Response and Placebo Effect: What Is the Difference?

  2025cites this paper
• Flickering lenses enhance reading performance through placebo effect

  2025cites this paper
• Quantifying placebo and trial participation effects on cognitive outcome measures in aging dogs

  2025cites this paper
• The motor system and motor disorders.

  2025cites this paper
• A brief history of placebo.

  2025cites this paper
• Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach

  2025cites this paper
• The concept of placebo/nocebo response and effect

  2025cites this paper
• Dose-extending placebo effect in a rat model of buprenorphine maintenance treatment.

  2025cites this paper
• Placebo and Nocebo Effects in Motor Performance: An Overview of Reviews

  2025cites this paper
• Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease

  2025cites this paper
• A narrative review of the placebo effect: historical roots, current applications, and emerging insights

  2025cites this paper
• Clinical neuroscience and neurobiology of placebo and nocebo effects.

  2025cites this paper
• Lower striatal dopamine D2 receptor availability in individuals who test positive for quantitated urine metabolites of tobacco and/or marijuana smoke.

  2025cites this paper
• Multi-omics characterization of improved cognitive functions in Parkinson’s disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial

  2025cites this paper
• Non-invasive brain stimulation to enhance sleep quality and architecture in Parkinson's disease: A systematic review and Bayesian network meta-analysis.

  2025cites this paper
• Placebo in Functional Neurological Disorders: Promise and Controversy

  2025cites this paper
• Development and Biomedical Application of Non-Noble Metal Nanomaterials in SERS

  2024cites this paper
• Transdermal Scopolamine for Treatment-Resistant Major Depressive Disorder

  2024cites this paper
• Short‐Term Cannabidiol with Δ‐9‐Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial

  2024cites this paper
• Placebo Effects Are Small on Average in the 7.5% CO2 Inhalational Model of Generalized Anxiety

  2024cites this paper
• The Use of Placebo effect in Chronic Pain: Theories and Strategies

  2024cites this paper
• Sham surgery for the trialing of cell-based therapies to the CNS may not be necessary.

  2024cites this paper
• Inpatient’s, therapist’s and staff’s expectations regarding treatment and their effects on placebo response in the psychiatric ward – results from an add-on oxytocin RCT

  2024cites this paper
• Dopamine has no direct causal role in the formation of treatment expectations and placebo analgesia in humans

  2024cites this paper
• Silane-Functionalized MXene-PEGDA Hydrogel for Enhanced Electrochemical Sensing of Neurotransmitters and Antioxidants

  2024cites this paper
• Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella review

  2024cites this paper
• Historical Perspectives of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies.

  2024cites this paper
• Factors associated with a placebo effect in Parkinson’s disease in clinical trials: a meta-analysis

  2024cites this paper
• The Role of Attention in Placebo and Nocebo Effects.

  2024cites this paper
• The Ethics of Placebo.

  2024cites this paper
• How brain structure–function decoupling supports individual cognition and its molecular mechanism

  2024cites this paper
• Open-Label Placebo Injection for Chronic Back Pain With Functional Neuroimaging

  2024cites this paper
• Kinésithérapie effectivement basee sur le placebo : comment les recherche de ces deux champs s’alimentent

  2024cites this paper
• EFFICACY OF MEDICATIONS FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD): A SYSTEMATIC REVIEW AND META-ANALYSIS CONSIDERING BASELINE AUD SEVERITY.

  2024cites this paper
• Three Faith-based Factors in Healing – A Need to Relook in Modern Medicine

  2024cites this paper
• Placebo Effect: The Stem of Seminal Studies with Active Treatment Neurobiological Mechanisms, And Implications for Parkinson’s Disease with Deep Brain Stimulation

  2024cites this paper
• Cell therapy for neurological disorders

  2024cites this paper
• Novel multi-modal methodology to investigate placebo response in major depressive disorder.

  2024cites this paper
• The Roles of Endogenous Opioids in Placebo and Nocebo Effects: From Pain to Performance to Prozac.

  2024cites this paper
• Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

  2023cites this paper
• Role of expectations in clinical outcomes after deep brain stimulation in patients with Parkinson’s disease: a systematic review

  2023cites this paper
• A Review on Non-Noble Metal Substrates for Surface-Enhanced Raman Scattering Detection

  2023cites this paper
• Nocebo effect as the opposite of the placebo effect: Systematic review

  2023cites this paper
• Psychopathologie et effet placebo en clinique de la douleur

  2023cites this paper
• Novel ultrasound neuromodulation therapy with transcranial pulse stimulation (TPS) in Parkinson’s disease: a first retrospective analysis

  2023cites this paper
• Functional Brain Networks to Evaluate Treatment Responses in Parkinson’s Disease

  2023cites this paper
• Placebo effects in mental health disorders: protocol for an umbrella review

  2023cites this paper
• Longitudinal Meta‐Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design

  2023cites this paper
• Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

  2023cites this paper
• Restless Legs Syndrome and Other Common Sleep-Related Movement Disorders

  2023cites this paper
• Procedure‐Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta‐analysis

  2023cites this paper
• From neurotransmitters to networks: Transcending organisational hierarchies with molecular-informed functional imaging

  2023cites this paper
• Placebo effect on gait: a way to reduce the dual-task cost in older adults

  2023cites this paper
• Placebo effect and its determinants in ocular hypotensive therapy: meta-analysis and multiple meta-regression analysis.

  2023cites this paper
• The effect of whole body vibration on gait stability in individuals with Parkinson's disease: a preliminary study

  2023cites this paper
• A fundamental change is needed for appraising placebo responses in psychiatry.

  2023cites this paper
• Are there placebo or nocebo effects in balancing performance?

  2023cites this paper
• How Do Expectations Modulate Pain? A Motivational Perspective

  2023cites this paper
• High throughput 3D gel-based neural organotypic model for cellular assays using fluorescence biosensors

  2022cites this paper
• Placeboeffekte in der Medizin

  2022cites this paper
• Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson’s disease are dependent on frontal function

  2022cites this paper
• Unpacking placebo and working memory training effects on cognitive performance

  2022cites this paper
• Non-invasive brain stimulation and neuroenhancement

  2022cites this paper
• Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders

  2022cites this paper
• The association between personality traits and placebo effects: a preregistered systematic review and meta-analysis.

  2022cites this paper
• Vinyl as Fine Wine: The Role of Expectation on the Perception of Music Format

  2022cites this paper
• Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy

  2022cites this paper
• Effects of Immediate Aversive Stimulation on Haloperidol-Induced Catalepsy in Rats

  2022cites this paper
• Placebo and nocebo effects: from observation to harnessing and clinical application

  2022cites this paper
• Levodopa effects on [ 11 C]raclopride binding in the resting human brain [version 1; peer review: 3 approved]

  2022cites this paper
• Stabilizing photo-induced vacancy defects in MOF matrix for high-performance SERS detection

  2022cites this paper
• The reward for placebos: mechanisms underpinning placebo-induced effects on motor performance

  2022cites this paper
• Phasic firing of dopaminergic neurons in the ventral tegmental area triggers peripheral immune responses

  2022cites this paper
• Methodological Considerations for Setting Up Deep Brain Stimulation Studies for New Indications

  2022cites this paper
• Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review

  2022cites this paper
• Insight Into the Effects of Clinical Repetitive Transcranial Magnetic Stimulation on the Brain From Positron Emission Tomography and Magnetic Resonance Imaging Studies: A Narrative Review

  2022cites this paper
• NeuroEPO and cognitive function in Parkinsons disease in a randomized placebo-controlled and post-trial studies

  2022cites this paper
• The Effect of Positive Therapeutic Communication on Pain (POPAIN) and Anxiety During Arterial Blood Gas Standardized Procedures in the Emergency Department Compared to Traditional Communication: Protocol for a Monocentric Randomized Controlled Trial

  2022cites this paper
• Oxytocin and the Social Facilitation of Placebo Effects

  2022cites this paper
• Morbus Parkinson

  2022cites this paper
• Assessing preoperative hope and expectations related to functional neurosurgery: a new questionnaire

  2022cites this paper
• Distinct neural networks subserve placebo analgesia and nocebo hyperalgesia

  2021cites this paper
• The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia

  2021cites this paper
• A candidate neuroimaging biomarker for detection of neurotransmission-related functional alterations and prediction of pharmacological analgesic response in chronic pain

  2021cites this paper
• SCIENTIFIC EVIDENCE OF HEALING WITH USE OF FAITH AND POSITIVE LANGUAGE IN PSYCHOTHERAPY

  2021cites this paper
• Assessing the Impact of Expectations in Cognitive Training and Beyond

  2021cites this paper
• Clinical Trials for Orthostatic Hypotension in Parkinson’s Disease and Other Synucleinopathies

  2021cites this paper